Clinical trial NCT01176227: Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)
Official title: The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Irritable Bowel Syndrome
Digestive System Diseases
Colonic Diseases, Functional
Colitis, Mucous
Colon, Irritable
Keywords: bloating
constipation
diarrhea
gas
mucous
cramping
Lead sponsor: The Canadian College of Naturopathic Medicine
Sponsor class: OTHER
Collaborators: name: Wakunaga Pharmaceutical Co., Ltd.
name: Dicentra Inc.
First posted: 2010-08-05
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America. It is a long term, recurring gastrointestinal disorder that is estimated to affect 30% of the general population. IBS is characterized by abdominal pain and cramps, and bowel dysfunction such as diarrhea and bloating.

The medicines that are currently used to help people with IBS are not as effective as we would like them to be. These medicines are usually only prescribed to reduce the pain of IBS and not actually treat the disorder itself. Recently, scientists have found that probiotics (beneficial bacteria that live inside humans) may help reduce the painful symptoms and diarrhea that are part of IBS.

This research is being conducted to determine whether this particular combination of three probiotic bacteria (named Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum) will reduce the symptoms of IBS.

Detailed description: The purpose of this trial is to investigate the effects of the three strain probiotic, Kyo-Dophilus, on the symptoms associated with Irritable Bowel Syndrome.

The primary objective of this trial is to determine the effectiveness of Kyo-Dophilus on the symptoms associated with Irritable Bowel Syndrome in an adult population diagnosed with Irritable Bowel Syndrome by ROME III criteria and classified as mild through the Irritable Bowel Severity Scoring System and to measuring quality of life and global well being of patients through the Visual Analog Scale and the Irritable Bowel Syndrome-Quality of Life Questioner. The secondary objective is to assess the tolerability of the treatment through the use of study diaries.

Eligibility criteria: Inclusion Criteria:

* Male and female subjects aged 18-64
* A diagnosis of Irritable Bowel Syndrome as per ROME III criteria
* A classification of mild irritable bowel syndrome as indicated by the Irritable Bowel Severity Scoring System (score \>75)
* Female subjects currently using an acceptable form of birth control who agree to maintain its use throughout the study (e.g. abstinence, oral contraceptives, barrier methods)
* Subjects who agree to maintain their current eating habits throughout the study
* Ability to understand and sign the Informed Consent Form

Exclusion Criteria:

* Female subjects who are breastfeeding, pregnant, or are open to becoming pregnant in the next three months
* Subjects currently receiving medication for the treatment of IBS symptoms
* Subjects currently receiving natural health products for treatment of IBS symptoms will be eligible for inclusion in the trial is they agree to undergo a two week washout period
* Subjects currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal pain
* Subjects who are immune-compromised (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment)
* Subjects currently receiving antibiotic therapy or antibiotic therapy within the previous month
* Subjects regularly consuming probiotic containing products (e.g. yogurts, etc.)
* Subjects who have recently (\< 3 months) initiated dietary measures to control IBS symptoms
* Subjects with a history of major or complicated gastrointestinal surgery
* Subjects with severe endometriosis
* Subjects with malignant tumors or subjects undergoing chemotherapy or radiation therapy
* Subjects with severe IBS and that require medication
* Subjects with weight loss, anaemia, inflammatory bowel disease, celiac sprue, family history of colorectal cancer
* Subjects exhibiting or indicating thoughts of suicide currently or in the past as based on patient screening interview by the investigator/clinician. Appropriate referral to a health care provider will be provided
* Subjects with known allergies to milk or milk based products
* Subjects using and/or have used antipsychotic or anticholinergic medication within the prior month, those with reported significant abnormalities on the thyroid function tests, blood counts and serum chemistry
* Subjects 50 years or older who have been diagnosed with IBS and have not received a colonoscopy in the last five years.

Primary outcomes:
measure: The irrtable bowel severity scoring system is the primary outcome measure
timeFrame: 12 weeks (between baseline and end of study)
Secondary outcomes:
measure: Tolerability of the treatment will be assessed through the use of study diaries in which adverse events will be recorded.
timeFrame: 12 weeks
measure: The Irritable Bowel Syndrome-Quality of Life Questionnaire
timeFrame: 12 weeks (baseline and end of study)
measure: Visual Analogue Scale
timeFrame: 12 weeks (baseline and end of study)
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Canadian College of Naturopathic Medicine
state: Ontario
Study officials:
affiliation: The Canadian College of Naturopathic Medicine
name: Dugald Seely, ND
role: PRINCIPAL_INVESTIGATOR
References: